[go: up one dir, main page]

MX2017005236A - Profarmacos de carbidopa y l-dopa y metodos de uso. - Google Patents

Profarmacos de carbidopa y l-dopa y metodos de uso.

Info

Publication number
MX2017005236A
MX2017005236A MX2017005236A MX2017005236A MX2017005236A MX 2017005236 A MX2017005236 A MX 2017005236A MX 2017005236 A MX2017005236 A MX 2017005236A MX 2017005236 A MX2017005236 A MX 2017005236A MX 2017005236 A MX2017005236 A MX 2017005236A
Authority
MX
Mexico
Prior art keywords
carbidopa
disease
treat parkinson
prodrug
dopa
Prior art date
Application number
MX2017005236A
Other languages
English (en)
Other versions
MX381069B (es
Inventor
A Matulenko Mark
A Voight Eric
J Stella Valentino
Lao Yanbin
Lou Xiaochun
S Chan Vincent
Wang Zhi
Huang Ye
G Zhang Geoff
Cardinal-David Benoit
E Dempah Kassibla
P Enright Brian
F Henry Rodger
Ho Raimundo
D Huters Alexander
C Klix Russell
W Krabbe Scott
R Kym Philip
E Mackey Sean
T Mayer Peter
P Miller Christopher
Stambuli James
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017005236(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2017005236A publication Critical patent/MX2017005236A/es
Publication of MX381069B publication Critical patent/MX381069B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/094—Esters of phosphoric acids with arylalkanols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/24—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
    • C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente descripción se refiere a (a) profármacos de carbidopa, (b) combinaciones y composiciones farmacéuticas que comprenden un profármaco de carbidopa y/o un profármaco de L-dopa, y (c) métodos para tratar mal de Parkinson y afecciones asociadas que comprenden administrar un profármaco de carbidopa y un profármaco de L-dopa al sujeto con mal de Parkinson.
MX2017005236A 2014-10-21 2015-10-21 Profármacos de carbidopa y l-dopa y métodos de uso. MX381069B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462066771P 2014-10-21 2014-10-21
PCT/US2015/056686 WO2016065019A1 (en) 2014-10-21 2015-10-21 Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease

Publications (2)

Publication Number Publication Date
MX2017005236A true MX2017005236A (es) 2017-07-26
MX381069B MX381069B (es) 2025-03-12

Family

ID=54478240

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017005236A MX381069B (es) 2014-10-21 2015-10-21 Profármacos de carbidopa y l-dopa y métodos de uso.
MX2021003840A MX393568B (es) 2014-10-21 2015-10-21 Profarmacos de carbidopa y l-dopa y metodos de uso

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021003840A MX393568B (es) 2014-10-21 2015-10-21 Profarmacos de carbidopa y l-dopa y metodos de uso

Country Status (37)

Country Link
US (7) US9446059B2 (es)
EP (3) EP3569587A1 (es)
JP (6) JP6567049B2 (es)
KR (3) KR20240113982A (es)
CN (4) CN111362980B (es)
AR (1) AR102389A1 (es)
AU (4) AU2015335941B2 (es)
BR (1) BR112017008198B1 (es)
CA (1) CA2965379A1 (es)
CY (2) CY1121826T1 (es)
DK (1) DK3209302T3 (es)
ES (1) ES2739536T3 (es)
FI (1) FIC20230014I1 (es)
FR (1) FR23C1035I2 (es)
HR (1) HRP20191285T1 (es)
HU (2) HUE044115T2 (es)
IL (3) IL251829B (es)
LT (2) LT3209302T (es)
LU (1) LUC00304I2 (es)
MX (2) MX381069B (es)
MY (1) MY189519A (es)
NL (1) NL301224I2 (es)
NO (1) NO2023013I1 (es)
PH (1) PH12017500746B1 (es)
PL (1) PL3209302T3 (es)
PT (1) PT3209302T (es)
RS (1) RS58972B1 (es)
RU (2) RU2743347C2 (es)
SA (1) SA521421115B1 (es)
SG (1) SG11201703170RA (es)
SI (1) SI3209302T1 (es)
SM (1) SMT201900376T1 (es)
TR (1) TR201908296T4 (es)
TW (2) TWI718999B (es)
UA (1) UA120437C2 (es)
WO (1) WO2016065019A1 (es)
ZA (1) ZA201702760B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
HRP20201948T1 (hr) 2014-03-13 2021-01-22 Neuroderm Ltd Pripravci inhibitora dopa-dekarbokilaze
KR20240113982A (ko) 2014-10-21 2024-07-23 애브비 인코포레이티드 카르비도파 및 l-도파 프로드럭 및 파킨슨병을 치료하기 위한 이들의 용도
JP2019515908A (ja) * 2016-04-20 2019-06-13 アッヴィ・インコーポレイテッド カルビドパ及びｌ−ドパプロドラッグ並びに使用方法
US11148999B2 (en) 2016-06-22 2021-10-19 MedChem Partners, LLC Nitric oxide donors
WO2018154447A1 (en) * 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
US20180311238A1 (en) * 2017-04-28 2018-11-01 Saniona A/S Selective Agonist Of a6 Containing nAChRs
WO2019097120A1 (en) 2017-11-16 2019-05-23 Orion Corporation New use and pharmaceutical dosage forms
PE20211290A1 (es) 2017-11-24 2021-07-20 H Lundbeck As Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad del parkinson
CN110294789A (zh) * 2018-03-21 2019-10-01 海南大学 含多巴寡肽的合成方法及其在抗帕金森病前药方面的应用
EP3849533A4 (en) 2018-09-13 2022-06-22 University of Canberra Methods of inhibition
TW202031265A (zh) 2018-11-15 2020-09-01 美商艾伯維有限公司 用於皮下投藥之醫藥調配物
WO2020178810A1 (en) * 2019-03-04 2020-09-10 Neuroderm, Ltd. Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
JP7641234B2 (ja) 2019-05-21 2025-03-06 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
WO2020234276A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
US12398106B2 (en) 2019-05-21 2025-08-26 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson's disease
EP3972971A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
EP4223288B1 (en) 2022-02-07 2024-03-06 Berlirem GmbH Novel kit of pharmaceutical preparations for the treatment of parkinson's disease
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US4016288A (en) * 1975-08-13 1977-04-05 Merck & Co., Inc. Compositions and method of treating hypertension
DD230865B1 (de) * 1982-08-09 1987-05-20 Dresden Arzneimittel Verfahren zur herstellung von hydrazinocarbonsaeurederivaten durch n-aminierung von aminocarbonsaeurederivaten
US4618484A (en) 1983-03-30 1986-10-21 Yale University Composition and method for treatment of melanomas
US4508706A (en) * 1983-03-30 1985-04-02 Yale University Composition for increasing melanin in mammalian skin and hair
IT1213182B (it) * 1984-06-25 1989-12-14 Simes Derivati di composti a struttura catecolamminica.
US4616484A (en) 1984-11-30 1986-10-14 Kysor Industrial Corporation Vehicle refrigerant heating and cooling system
IT1200427B (it) 1985-03-22 1989-01-18 Afros Spa Procedimento ed impianto per lo stampaggio di pezzi in materiale plastico espanso,con parti o inserti preformati a spruzzo nello stesso stampo di formatura
JPH02138A (ja) 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd Ｌ‐ドーパ誘導体
IT1226727B (it) 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
EP0393781B1 (en) * 1989-04-20 1995-02-08 ZAMBON GROUP S.p.A. Dopamine pro-drug
GB9102812D0 (en) 1991-02-11 1991-03-27 Enzymatix Ltd Compounds
IT1255471B (it) 1992-07-30 1995-11-02 Zambon Spa Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono
SE9203594D0 (sv) 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
CA2309792A1 (en) * 1997-11-12 1999-05-20 William C. Shakespeare Novel signal transduction inhibitors, compositions containing them
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
KR20050016449A (ko) * 2002-05-29 2005-02-21 임팩스 라보라토리즈, 인코포레이티드 레보도파/카르비도파의 즉시 방출 및 제어 방출 조합 투여형
WO2004000863A1 (ja) 2002-06-20 2003-12-31 Nippon Suisan Kaisha, Ltd. プロドラッグ、その医薬としての使用、およびその製法
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
WO2004069146A2 (en) 2003-02-07 2004-08-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-dopa amide derivatives and uses thereof
CN1845728B (zh) * 2003-08-29 2013-06-19 转化医药公司 包含左旋多巴和卡比多巴的药物组合物
ATE495739T1 (de) 2003-08-29 2011-02-15 Transform Pharmaceuticals Inc Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
CA2543181A1 (en) 2003-10-31 2005-05-12 Alza Corporation Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin
CN101023056B (zh) 2004-06-04 2011-05-25 克塞诺波特公司 左旋多巴前药、和组合物及其应用
AU2005270124B2 (en) 2004-07-06 2011-09-08 Abbvie Inc. Prodrugs of HIV protease inhibitors
WO2007067495A2 (en) * 2005-12-05 2007-06-14 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
RU2484815C2 (ru) * 2006-05-31 2013-06-20 Зольвай Фармасьютиклз Гмбх Продолжительное 24-часовое введение в кишечник леводопа/карбидопа
AU2007259256A1 (en) * 2006-06-16 2007-12-21 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and L-DOPA
WO2008076458A1 (en) 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
GB0713189D0 (en) 2007-07-06 2007-08-15 Proximagen Ltd Amino acid derivatives
NZ587168A (en) * 2008-02-06 2011-06-30 Wockhardt Research Center Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
BRPI0912326A2 (pt) 2008-05-20 2015-10-06 Neurogesx Inc análogos de acetaminofeno hidrossolúveis
DK3192500T3 (da) 2009-05-19 2020-12-21 Neuroderm Ltd Sammensætninger til kontinuerlig indgivelse af dopa-decarboxylasehæmmere
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
ES2565644T3 (es) 2009-11-09 2016-04-06 Xenoport, Inc. Composiciones farmacéuticas y formas de dosificación oral de un pre medicamento de levodopa y los métodos de utilización
WO2011109767A2 (en) 2010-03-04 2011-09-09 University Of Notre Dame Du Lac Gelatinase inhibitors and prodrugs
EP3326615B1 (en) 2010-11-15 2020-01-08 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
BR112013013551A2 (pt) 2010-12-02 2016-10-11 Ono Pharmaceutical Co composto e uso médico do mesmo
US20140088192A1 (en) 2010-12-10 2014-03-27 Synagile Corporation Subcutaneously infusible levodopa prodrug compositions and methods of infusion
WO2012158527A2 (en) * 2011-05-13 2012-11-22 Howmedica Osteonics Organophosphorous & multivalent metal compound compositions & methods
KR20130070371A (ko) * 2011-12-19 2013-06-27 울산대학교 산학협력단 퇴행성 신경질환 예방 또는 치료용 조성물
AU2014229127B2 (en) 2013-03-13 2018-04-05 Neuroderm Ltd Method for treatment of parkinson's disease
CA2917145C (en) 2013-03-15 2023-10-24 Techfields Pharma Co., Ltd. Novel high penetration drugs and their compositions thereof for treatment of parkinson diseases
KR20240113982A (ko) * 2014-10-21 2024-07-23 애브비 인코포레이티드 카르비도파 및 l-도파 프로드럭 및 파킨슨병을 치료하기 위한 이들의 용도
MA41377A (fr) 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
JP2019515908A (ja) 2016-04-20 2019-06-13 アッヴィ・インコーポレイテッド カルビドパ及びｌ−ドパプロドラッグ並びに使用方法
EP3518920A1 (en) 2016-09-29 2019-08-07 Berlirem GmbH L-dopa derivatives for the treatment of neurological diseases
WO2018154447A1 (en) 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions

Also Published As

Publication number Publication date
JP2021183628A (ja) 2021-12-02
MY189519A (en) 2022-02-16
US11091507B2 (en) 2021-08-17
IL268885B (en) 2020-08-31
JP6567049B2 (ja) 2019-08-28
BR112017008198A2 (pt) 2017-12-26
FR23C1035I1 (fr) 2023-12-08
PT3209302T (pt) 2019-07-19
IL276493A (en) 2020-09-30
TW201630924A (zh) 2016-09-01
AU2025238004A1 (en) 2025-10-16
RU2017117413A3 (es) 2019-05-30
CY2023010I1 (el) 2023-06-09
HUE044115T2 (hu) 2019-10-28
KR20170071599A (ko) 2017-06-23
FIC20230014I1 (fi) 2023-03-31
CN111454290A (zh) 2020-07-28
CN111362980A (zh) 2020-07-03
NZ769153A (en) 2024-04-26
CN111362980B (zh) 2022-10-18
JP6932227B2 (ja) 2021-09-08
KR20230066484A (ko) 2023-05-15
TWI755257B (zh) 2022-02-11
SA521421115B1 (ar) 2022-03-01
FR23C1035I2 (fr) 2025-04-18
CN111494395B (zh) 2024-06-21
IL251829A0 (en) 2017-06-29
LUC00304I2 (es) 2025-09-22
EP4186510A1 (en) 2023-05-31
JP2023174770A (ja) 2023-12-08
LT3209302T (lt) 2019-06-10
CN111494395A (zh) 2020-08-07
MX381069B (es) 2025-03-12
UA120437C2 (uk) 2019-12-10
SI3209302T1 (sl) 2019-06-28
CA2965379A1 (en) 2016-04-28
PL3209302T3 (pl) 2019-10-31
MX2021003840A (es) 2022-06-30
US20160106765A1 (en) 2016-04-21
TR201908296T4 (tr) 2019-06-21
JP7688087B2 (ja) 2025-06-03
JP6750076B2 (ja) 2020-09-02
SMT201900376T1 (it) 2019-09-09
PH12017500746A1 (en) 2017-10-30
CY1121826T1 (el) 2020-07-31
NO2023013I1 (no) 2023-03-20
AR102389A1 (es) 2017-02-22
KR102537018B1 (ko) 2023-05-30
PH12017500746B1 (en) 2021-12-15
NZ730996A (en) 2024-04-26
JP2017537066A (ja) 2017-12-14
EP3209302B1 (en) 2019-04-24
DK3209302T3 (da) 2019-05-13
MX393568B (es) 2025-03-24
LTPA2023519I1 (es) 2023-06-26
IL251829B (en) 2019-09-26
NL301224I2 (nl) 2023-08-16
US20220153765A1 (en) 2022-05-19
JP2025118978A (ja) 2025-08-13
EP3209302A1 (en) 2017-08-30
NL301224I1 (es) 2023-03-29
WO2016065019A1 (en) 2016-04-28
HRP20191285T1 (hr) 2019-10-18
US20200262852A1 (en) 2020-08-20
US10174061B2 (en) 2019-01-08
HUS2300009I1 (hu) 2023-03-28
US10730895B2 (en) 2020-08-04
US20160362431A1 (en) 2016-12-15
AU2015335941B2 (en) 2021-04-01
CN107206013A (zh) 2017-09-26
KR20240113982A (ko) 2024-07-23
RU2021103000A (ru) 2021-03-01
BR112017008198B1 (pt) 2021-02-09
ES2739536T3 (es) 2020-01-31
US20180079762A1 (en) 2018-03-22
AU2021201414A1 (en) 2021-03-25
RU2017117413A (ru) 2018-11-26
AU2023210650A1 (en) 2023-08-24
ZA201702760B (en) 2022-05-25
US9446059B2 (en) 2016-09-20
CY2023010I2 (el) 2023-06-09
IL268885A (en) 2019-10-31
RS58972B1 (sr) 2019-08-30
US20190375770A1 (en) 2019-12-12
SG11201703170RA (en) 2017-05-30
TWI718999B (zh) 2021-02-21
EP3569587A1 (en) 2019-11-20
LTC3209302I2 (es) 2025-10-10
AU2021201414B2 (en) 2023-05-11
RU2743347C2 (ru) 2021-02-17
TW202131931A (zh) 2021-09-01
CN111454290B (zh) 2022-12-23
JP2019218356A (ja) 2019-12-26
AU2015335941A1 (en) 2017-05-04
US20230106081A1 (en) 2023-04-06
JP2020189864A (ja) 2020-11-26

Similar Documents

Publication Publication Date Title
MX2017005236A (es) Profarmacos de carbidopa y l-dopa y metodos de uso.
WO2017184871A9 (en) Carbidopa and l-dopa prodrugs and methods of use
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
MX369041B (es) Proteinas quimericas tipo fosfatasa alcalina.
CO2018003224A2 (es) Formulaciones de aminoacidos de liberacion modificada administradas oralmente
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
CO2019008103A2 (es) Composiciones farmacéuticas para terapia de combinación
MX386055B (es) Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson.
CL2017003124A1 (es) Moduladores alostéricos positivos del receptor de m2 muscarínico
BR112017014598A2 (pt) métodos e usos para hidrólise de queratina
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
BR112018072255A2 (pt) azasteroides para tratamento de tuberculose
CL2019002174A1 (es) Composición que comprende capecitabina de liberación inmediata y liberación prolongada.
BR112018077112A2 (pt) uso de liso-gb1 como alvo capaz de ser modulado por um fármaco
BR112018012313A2 (pt) composições que compreendem 15-hepe e métodos para uso das mesmas
AR102995A1 (es) Uso de ligandos del receptor sigma en la osteoartritis
IN2013MU03855A (es)